Figure. Progression-Free Survival and Overall Survival in Unmatched and Matched Populations of Patients With Enteropancreatic Neuroendocrine Tumors Who Received Upfront Peptide Receptor Radionuclide Therapy (PRRT) or Upfront Chemotherapy (CT) or Targeted Therapy (TT).

Shaded areas represent X.